Показать сокращенную информацию
dc.contributor.author | Begaydarova, R. Kh. | |
dc.contributor.author | Starikov, Yu. G. | |
dc.contributor.author | Alshynbekova, G. К. | |
dc.contributor.author | Dautova, B. M. | |
dc.contributor.author | Abdrakhmanova, D. G. | |
dc.date.accessioned | 2023-08-29T03:33:02Z | |
dc.date.available | 2023-08-29T03:33:02Z | |
dc.date.issued | 2018-01 | |
dc.identifier.uri | http://repoz.kgmu.kz/handle/123456789/656 | |
dc.description.abstract | 100 children from 2 to 10 years of age including with bronchopulmonary pathology of viral-bacterial etiology were examined for the purpose of studying the clinical efficacy and safety of the use of Inspiron. The main group of 50 children received Inspiron, control (50 people) – ambroxol. The efficacy and safety of the drug was assessed by the dynamics of bronchial obstructive syndrome, cough, dyspnea, physical parameters of the respiratory system, tolerability and the presence of allergic reactions. The carried out researches have shown high efficiency of the preparation «Inspiron». A pronounced bronchoobstructive, mucolytic, antitussive effect was revealed, and an easier withdrawal of sputum was recorded. In no case are allergic reactions or laryngospasm recorded. There was a significant reduction in the stay of children in the hospital, which led to a reduction in the costs of the medical institution for treatment and examination. | en_US |
dc.subject | Inspiron | en_US |
dc.subject | ambroxol | en_US |
dc.subject | broncho-obstructive syndrome | en_US |
dc.subject | cough | en_US |
dc.subject | dyspnea | en_US |
dc.title | Inspiron in bronchopulmonary pathologies of viral-bacterial etiology in children | en_US |
dc.type | Article | en_US |